H.C. Wainwright Maintains BioXcel Therapeutics(BTAI.US) With Buy Rating, Cuts Target Price to $5
BioXcel Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | BioXcel Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $5 From $7
BioXcel Announces Defense Grant to UNC to Fund Study for Treating Acute Stress Disorder
Express News | BioXcel Therapeutics Inc - Phase 2a Trial Enrollment Expected in H1 2025
Express News | BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of Bxcl501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder
BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder
Bioxcel Therapeutics Senior VP Wiley Transitions to Consultant
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Arcutis Biotherapeutics (ARQT)
BioXcel Ends Commercial Support for Igalmi as Focus Turns to Neuro Candidate
Bioxcel Therapeutics Announced Its Clinical Prioritization, While Deprioritizing Sales Efforts For Its Approved Drug Igalmi (Dexmedetomidine) Sublingual Film. The Company Plans To Maintain Igalmi In The Market Without Its Current Commercial Infrastructure
Bioxcel Therapeutics Announces Restructuring and Leadership Changes
Express News | BioXcel Therapeutics Inc - Estimates It Will Incur Aggregate Charges in Connection With Clinical Prioritization of About $1.4 Mln
Express News | BioXcel Therapeutics Inc - Plan to Reduce Its Workforce by 15 Employees, or About 28% of Company's Headcount
BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation
Bioxcel Therapeutics Executive Sells Over $148 in Stock
Mizuho Securities Maintains BioXcel Therapeutics(BTAI.US) With Hold Rating, Announces Target Price $1
Mizuho Securities analyst Graig Suvannavejh maintains $BioXcel Therapeutics(BTAI.US)$ with a hold rating, and sets the target price at $1.According to TipRanks data, the analyst has a success rate
HC Wainwright & Co. Reiterates Buy on BioXcel Therapeutics, Maintains $7 Price Target
Bioxcel Therapeutics Earns Buy Rating on Promising Clinical Trials and Market Potential
Express News | BioXcel Therapeutics Inc - Trial Duration Expected to Be 9 to 12 Months